The development of a sensitive and specific enzyme-linked immunoassay (ELISA) for inhibin A stimulated the observation that inhibin A was a useful prenatal marker of Down's syndrome. Modifications of that ELISA, in terms of preassay sample treatment, detection methods and standard preparation, were subsequently introduced to improve assay performance and reduce costs. These modified formats have been validated and reported. We describe the modifications in detail, explaining the rationale for each, and report the results of a study directly comparing the various ELISA formats in terms of assay performance when applied to clinical samples and ability to differentiate between normal and Down's syndrome pregnancies. A format involving sample pretreatment with sodium dodecylsulphate at lOODe was found to give better assay performance and a modest improvement in discrimination between Down's syndrome samples and controls, and we recommend this format for use by other investigators.
SUMMARY. The development of a sensitive and specific enzyme-linked immunoassay (ELISA) for inhibin A stimulated the observation that inhibin A was a useful prenatal marker of Down's syndrome. Modifications of that ELISA, in terms of preassay sample treatment, detection methods and standard preparation, were subsequently introduced to improve assay performance and reduce costs. These modified formats have been validated and reported. We describe the modifications in detail, explaining the rationale for each, and report the results of a study directly comparing the various ELISA formats in terms of assay performance when applied to clinical samples and ability to differentiate between normal and Down's syndrome pregnancies. A format involving sample pretreatment with sodium dodecylsulphate at lOODe was found to give better assay performance and a modest improvement in discrimination between Down's syndrome samples and controls, and we recommend this format for use by other investigators.
Additional key phrases: trisomy 21; prenatal screening; pregnancy; immunoassay It has been shown recently that the maternal serum inhibin A level in a Down's syndrome pregnancy is, on average, significantly elevated compared with that in normal pregnancy!" and that, when combined with existing prenatal serum markers, inhibin A may increase the detection rate of Down's syndrome in the second trimester by up to 20% . 4,5.7 Subsequent to the development and original description of the inhibin A enzyme-linked immunosorbent assay (ELISA) used in previous studies." a number of modifications have been described by Groome and colleagues.v'? These modifications have afforded both improved assay performance and significant cost improvements, as will be shown in this manuscript. However, the use of different assay formats, and different inhibin standard preparations within Correspondence: Dr E M Wallace. E-mail:Euan.Wallace@med.monash.edu.au 656 those formats, has resulted in considerable variation in the absolute levels of inhibin A reported, making direct comparisons between studies difficult. There have also been variations in the discrimination between Down's syndrome cases and controls reported by different groups. I 7 This observation may have been simply caused by chance, regression to the mean, or to differences in the sample sets, but an effect related to the assay modifications could not be excluded.
We therefore undertook a detailed comparative study of the various inhibin A ELISA formats when applied to serum samples from both normal and Down's syndrome pregnancies.
MATERIALS AND METHODS

Inhibin A ELISA
The inhibin A two-site ELISA, as described by Groome and O'Brien" and previously validated for human serum, II was used throughout this study but with a number of modifications. The assay utilizes an immobilized anti-fJA-inhibin subunit monoclonal antibody (E4) as a capture antibody, covalently coupled to hydrazide microplates (Avidplate-HZ, UniSyn Technologies, Justin, CA, USA). The Fab fraction of a mouse anti-z-inhibin subunit monoclonal antibody (R I) is used as a second antibody and is conjugated to alkaline phosphatase, allowing detection by the addition of an alkaline phosphatase substrate. The cross-reactivity of this assay with activin-A, activin-B, follistatin, purified human pro-ocC and inhibin B is less than 0·1 %. The modifications that were developed included changes to pre-assay sample preparation and the method of signal detection, essentially giving rise to three different methods, referred to as formats I to III below. Furthermore, the standard preparation used was also changed and the two preparations are detailed separately.
Method modifications
Format I Prior to assay, hydrogen peroxide was added to each sample or standard to a final concentration of 10gjL and samples were then incubated at room temperature for 30 min and diluted I: I in assay diluent (0,1 M Tris HCI, 0·15M NaCI with 5% Triton XIOO, 10% bovine serum albumin, and 5% normal mouse serum, pH 7'5). This peroxide step modifies the fJ-subunit epitopes to improve reactivity with the antibodiesl-and thereby increases the assay sensitivity. The method of signal detection used in this method is as described previously. \I An amplified enzyme assay (Life Technologies, Paisley, UK) results in colour change and the absorbance at 490 nm is measured after 20-30 min in a microplate reader (Thermomax, Molecular Devices Corp., Menlo Park, CA, USA) using dedicated software (Softmax, Molecular Devices Corp.). Results are expressed as pgjmL. The detection limit (defined as the concentration corresponding to two standard deviations above the mean signal for 30 replicate zero standards) of the assay is 8 pgjmL and the intra-and interplate coefficients of variation are 4·7% and 10%, respectively.
Format 1/
This method is identical to method I except for the method of signal detection. The high sensitivity developed in the original method,
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while required for the detection of inhibin A throughout the human menstrual cycle,'! was not required for the very high levels of inhibin A in pregnancy sera.l-!" A simplified and cheaper method of detection using a non-amplified alkaline phosphatase substrate, p-nitrophenylphosphate (pNPP; Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA) was therefore validated by Groome and results using this single modification were first described by Noble and her colleagues." Using this method, plates are read after 2---4 h at 405 nm in a microplate reader as before. Results are expressed as pgjmL with an assay detection limit (defined as above) of 23 pgjmL. The intraplate and interplate coefficients of variation are 5·6% and 6,3%, respectively.
Format III
This method involves an additional sample preparation step, performed prior to oxidation. During the early application of the assay to clinical serum samples we observed that signals could not be obtained from some samples, particularly (though not exclusively) those with evidence of haemolysis. This was believed to be caused by a reaction between catalase, released by red blood cells on lysing, and the peroxide, quenching the oxidative effect on the inhibin. Recently, Groome and his colleagues developed and described ELiSAs similar to the inhibin A assay but specific for inhibin Band activin A. 13 , 14 These assays incorporated a pretreatment step, involving heating the sample or standard in a waterbath at 100 DC for 3 min after mixing with sodium dodecylsulphate (SDS) to a final concentration of 20 gjL. This was found to remove interfering substances from the samples effectively, and was subsequently applied to the inhibin A assay. While parallelism, recovery and sensitivity of the modified assay are comparable to the original method (Groome, unpublished data), it was observed that with the modification signals could be generated from all samples, including those in which no inhibin had been previously detectable. Detection is afforded by the addition of pNPP as detailed in method II. Results are expressed as pgjmL with an assay detection limit of 23 pgjmL. The intra-and interplate co-efficients of variation are 4·9% and 8'7%, respectively. This format has been validated recently for use in serum and amniotic fluid 10 and has been used for inhibin A measurement in two separate series of Down's syndrome samples.>"
Standard preparations Preparation I (RH)
The standard preparation used in the initial reports of this assayl,2,4,9,IJ was 32 kD recombinant human (RH) inhibin supplied by Genentech Inc (San Francisco, CA, USA).
Preparation II (IP)
Subsequent to the above studies, a new standard preparation was developed by Groome, allowing the commercial distribution of the assay. This is partially immunopurified from follicular fluid, using an anti-a-subunit antibody (RI), and is calibrated against the RH in hibin using assay format I. Six possible permutations of the formats and standards are therefore possible and were compared in this study: I-IP, II-IP, III-IP, I-RH, II-RH, III-RH (format-standard).
Samples
A stability study was performed to explore the possibility that storage could affect the level of inhibin detected (probably through the leakage of catalase from red blood cells). Blood was collected, with consent, by routine venepuncture from 10 healthy women in mid-pregnancy. Each sample was divided into 2 aliquots. One aliquot was centrifuged and the other was kept un separated at room temperature. The serum from the first aliquot was further divided into three subaliquots, one of which was frozen at -20°C immediately. The remaining two serum subaliquots were kept at room temperature with subsequent frozen storage ( -20°C) of one after 24 h and the other after 48 h. The second whole blood aliquot was divided into 2 subaliquots. These were centrifuged at 24 and 48 h, allowing frozen storage (-20°C) of the serum at those times. Inhibin A levels were measured using assay formats II and III with the IP standard.
To compare the different assay formats in the detection of Down's syndrome, second trimester maternal sera from 41 Down's syndrome pregnancies and 247 control samples, matched for gestation and duration of storage, were identified from records and retrieved. None of the Down's syndrome or control samples had been assayed for inhibin A previously and each sample was assayed without knowledge of which group it was from. All assays were performed by the same individual (SCR) and each sample was assayed by all three formats with both standards consecutively, without further freeze-thawing.
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Where appropriate, ethical approval was granted by the Lothian Paediatric and Reproductive Medicine Research Ethics Subcommittee.
Statistical analyses
Statistical analyses were performed using the software packages Statview 4.1 (Abacus Inc., Berkeley, CA, USA) and SPSS (SPSS Inc., Chicago, IL, USA), The concentrations of inhibin A in blood/serum during storage were subjected to two-way analysis of variance (ANOVA) for repeated measures. The logarithm of the inhibin A concentration fits a Gaussian distribution and therefore comparisons of absolute concentrations were made using loglO concentration. Because inhibin concentrations vary significantly with gestation.!? regressed medians were calculated for each week of gestation, as previously described." and concentrations in samples from the Down's syndrome group were expressed as multiples of these normal medians (MoMs). MoMs obtained with different formats were compared by Wilcoxon rank sums for paired tests, Distribution parameters were calculated for inhibin A for each of the formats. The mean was taken as loglO median and the standard deviation as the difference between the 10th and 90th centiles in logs, divided by 2·56,15 except in cases when deviation in linearity occurred in the lower tail of the distribution when the 20th to 90th centile range was used, divided by 2·12. The predicted detection rate for Down's syndrome at a fixed 5% false positive rate using inhibin A and maternal age was calculated using an age model of the West of Scotland pregnant population. Comparative analyses were recorded as significant when P<O·05. Figure I shows the mean inhibin A concentration in the 10 samples under various storage conditions, as measured by assay formats II and III. Using format II (no pre-assay boiling step), the mean inhibin A level in samples stored as whole blood declined significantly (P<O·OI), with a fall of 42% at 48 h, whereas levels were stable for the samples stored as serum. When format III was employed, however, no significant changes in the mean inhibin A level were observed, regardless of how the samples had been stored. Format comparison study An assay problem was encountered for the first batch of samples assayed with format I (both standards). There was not sufficient sample to re-assay these samples and so data are available for this format for fewer samples (both controls and Down's syndrome groups) than the other two formats. Further, there was insufficient volume in another Down's syndrome sample to perform all three assay formats and so there are no data available on this sample assayed by format III. Median inhibin A levels in the control samples differed between the formats, with levels obtained by format III-RH in particular approximately double those of the other formats (see Table I ). Probability plots of the distribution of the Down's syndrome and control populations showed that data derived with formats I and II deviated significantly from Gaussian linearity, irrespective of the standards used (Figs 2 and 3) . To assess the spread of the population, standard deviations for these data were calculated from the 20th to 90th centile range. The probability plot for format III showed Gaussian linearity for both standards (Fig. 4 ) and the standard deviations were thus calculated from the 10th and 90th centile range. The parameters of inhibin A distribution in the control and Down's syndrome samples varied between formats, with format III affording the narrowest width of distribution, irrespective of the standard used (see Table 2 ). The median inhibin A level in the Down's syndrome samples, expressed as MoMs, was significantly higher in formats II and III when derived with the RH standard than when derived with the IP standard (see Table 2 , P < 0·0001 for both). There were no significant differences between standards for format I (P = 0,09). For a given standard preparation, no particular format afforded persistently higher Down's syndrome MoMs than the others, although, for the, RH standard, the median MoM was significantly higher when derived with format III than with format II (P = 0'02) and for the IP standard, higher with format I than with format II (P = 0,01). There were no other significant Table 2. differences. Consistent with these trends, the Mahalanobis distance from the control mean, a measurement of separation of the Down's syndrome population from the controls, was greatest with format III. Table 3 shows the correlation coefficients between loglO(inhibin A) levels in the control and Down's syndrome samples obtained by the different formats. The highest coefficients of correlation are between levels derived from the two different standard preparations within a given assay method. Furthermore, there is generally a high level ofcorrelation between the levelsobtained with assay formats I and II (irrespective of standard preparation), whereas the inhibin values derived with assay format III correlate less well with those from the other two formats.
RESULTS
Stability study
Predicted detection rates for Down's syndrome at a 5% false positive rate for formats a a II and III using inhibin A concentration and age are shown in Table 4 . We considered that there were insufficient data from Down's syndrome samples analysed with format I to estimate detection rates. Format III-RH gave the highest predicted detection rate but there was little difference in the detection rate by either format II or III with either standard.
DISCUSSION
We have described in detail the progressive evolution of an inhibin A ELISA used in a number of recent studies of Down's syndrome pregnancies, explaining both the rationale behind that evolution and, for the first time, providing formal comparative data from the different formats. As is apparent from the literature, our data confirm that there are significant differences in absolute levels of inhibin reported depending on the ELISA format and standard preparation used (see Table  I ). We recently highlighted these differences.?
and are now able to explain them objectively. Because the three ELISA formats remain highly specific for inhibin A and because the IP standard was calibrated against the RH standard, differences between the formats must be caused by variations in the efficacy of the formats to detect inhibin A and not by the detection of other inhibin moieties. Biological fluids contain a number of different molecular weight forms of inhibins.l'r!? The higher molecular weight forms of inhibin A, as well as being biologically inactive.P are less immunoreactive in the inhibin A ELISA used here than is 32 kDa inhibin A.21,22 However, the immunoreactivity of the larger forms can be increased approximately two-fold by boiling before assay.20 This effect cannot be secondary to TABLE 
Correlation coefficients (r) between log/(,(inhihin A) in Down's syndrome and control samples for the three assay formats (I-Ill) and two standard preparations
Il-RH 0·67 0·56 IP = preparation II (see text); RH = recombinant human inhibin; upper values = controls, lower values = Down's syndrome. degradation, because the large inhibin forms used were engineered to be non-cleavable, and so presumably arose by improving epitope exposure, perhaps through protein unfolding. The extent of this effect after boiling is similar to the approximately two-fold increase in inhibin A levels observed in our study with format III compared with the other two formats. That this difference is only evident with Ill-RH, and not Ill-IP, is explained by the composition of the two standard preparations. The RH standard, a recombinant preparation, contains only 32 kDa inhibin A and boiling in SDS would thus not be expected to change the already optimum antibody-epitope binding. However, boiling would improve antibody binding to the epitopes of the larger molecular weight inhibin A forms present in the unknown samples. The net effect, therefore, is a relative increase in the inhibin A measured against the recombinant standards. The IP standard, however, was derived from human follicular fluid, which contains inhibins of many different molecular weights.lv'? Thus, when the IP standard is employed to derive unknown values, the effect of boiling is exerted on both the standard and the sample resulting in minimal change in absolute inhibin levels. The net effect depends on the relative concentrations of the different forms in the standard (derived from follicular fluid) and sample (serum). The poor correlations between inhibin A levels from format III and formats I or II is probably not caused by differential detection of various inhibin A forms. If this was so then a poor correlation would be expected between the levels derived with III-IP and those with III-RH. This was not observed. We believe that the differences relate to the release of erythrocyte catalase in the venous samples. Catalase would remove the hydrogen peroxide added during pretreatment and thus prevent modification of the inhibin fJ-subunit and impair detection. This effect is evident in some samples, presumably Ann Clin Biochem 1998: 35 depending on storage/separation history, when assayed by formats I and II, but would be overcome by the SDS boiling pretreatment in format III, probably through the denaturing of the catalase. While we were unable to measure catalase in the samples to confirm this directly, indirect evidence is offered by our stability data. These showed that inhibin A concentrations fell when samples were stored as whole blood but not as serum and that when the samples were boiled prior to assay the decline was prevented. Thus, the changes observed with format II (no boiling) could not have been caused by dissociation of the inhibin dimer (perhaps by microbes, as has been recently reported for hCG B ) because levels were stable with format III (SDS boiling). Rather, the effect was related to storage as whole blood but not as serum, consistent with the release of erythrocyte catalase. Importantly, a quenched inhibin A signal was evident in the stability study samples even without obvious haemolysis, reflecting our experience of the original ELISA format when used with clinical samples (unpublished data). These data therefore suggest that while the apparent inhibin A concentration is stable in clinical samples, this is only so when using format III. This is important in the context of possible prenatal screening programmes, when samples might travel for some distance and time prior to assay. We have also performed repetitive freeze-thaw cycle stability studies which showed stability over 6 cycles, irrespective of the assay format used (data not shown).
Further support to the catalase hypothesis is given by the finding that the correlation coefficient between results from formats II-IP and III-IP can be increased by restricting analysis to those samples with an inhibin A level of at least 70 pg/ml, in formats I and II (r = O' 76 1'.1' r = 0·6 I). This value of 70 pg/ml, approximates to the 10th centile'" and so excludes many samples that may have an inhibin A level artefactually lowered by catalase. Similarly, the tighter distribution of results with format III compared with the other two formats is probably an effect of normalizing the levels in some samples with a quenched signal.
The high degree of correlation between the results derived with formats I and II suggests that, while there may be small differences in absolute levels detected, the method of detection of inhibin A in the ELISA is not of critical importance so long as expected levels are above the detection limit of the method used.
In this study, the boiling pretreatment was associated with an apparent modest improvement in the discrimination between Down's syndrome samples and controls (see Tables 2 and 4 ). To aid interpretation of these data in the context of the existing literature, Table 5 summarizes the previous second trimester studies, detailing the format used in each. Interestingly, the most recent, and largest, of these studies utilized format III-Ip6 and reported results less promising than the earlier studies using format 1. 3 ,4 Considering the biology underlying the differences between the formats and our current understanding of inhibin A in normal and Down's syndrome pregnancy.P-" we believe that it is unlikely that the assay format will impact significantly upon detection rates (Tables 4 and 5 ). In support of this, two sample sets reported from the same centre, one analysed with format 1 2 and one with format m.' showed no significant differences in terms of median MoMs.
CONCLUSION
We have undertaken a formal comparison of three different formats of an inhibin A ELISA that has been described in the literature for Down's syndrome screening. We have explained the rationale for introduction of the modifications and demonstrated that, while absolute TARLE 5. Inhihin A enzyme-linked immunosorbent assay (ELISA) method used and median inhibin A multiples of the median (MoM) in affected pregnancies reported in previous second trimester studies levels of inhibin A reported depend on the assay format and standards used, the discrimination of Down's syndrome cases from controls would not appear to be significantly affected. Nonetheless, the boiling pretreatment affords significant improvements in assay performance, particularly for samples stored as whole blood, and on this basis format III would appear to be the most useful clinically. The introduction of an internationally agreed inhibin A standard 26 will prevent other differences between laboratories, but until this is widely used a given institution should plan to use the same standard preparation for their long-term studies.
